** Shares of Emyria EMD.AX rise 2.9% to A$0.036, their highest levels since Dec 11
** The early-stage drug developer announces positive interim analysis results of its MDMA-assisted therapy programme for Post Traumatic Stress Disorder (PTSD)
** Co says therapy programme clinically reduces PTSD symptoms in first eight patients
** Stock rose as much as 14.3% to A$0.040 earlier in the day, marking its biggest intraday gain since Jan 22
** About 1.3 mln shares change hands, 6.9 times the 30-day average of 189,038
** Stock has risen 5.9% YTD, including current session's moves
(Reporting by Manasi Dasa Sundeep in Bengaluru)
((Manasi.DasaSundeep@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。